ວັກຊີນໂຄວິດ-19 BBIBP-CorV ຂອງຊິໂນຟາມ

COVID-19 (disease)Timeline2019
2020
 January
 February
 responses
 March
 responses
 April
 responses
 May
 responses
 June
 responses
 July
 responses
 August
 responses
 September
 responses
 October
 responses
 November
 responses
 December
 responses

2021

 January
 responses
 February
 responses
 March
 responses
 April
 responsesLocations By continent

 Africa
 Antarctica
 Asia
 Europe
 North America
 Oceania
 South America

 By conveyance

 Cruise ships
 Naval ships
 Cases
 DeathsInternational response European Union response
 Evacuations
 Face masks
 International aid
 Lockdowns
 National responses
 India
 New Zealand
 Philippines
 Russia
 Sweden
 U.K.
 U.S.
 Protests
 U.S.
 Travel restrictions
 United Nations
 World Health OrganizationMedical response Disease testing
 COVID-19 vaccines

 CanSino
 Gamaleya
 Johnson & Johnson
 Moderna
 Oxford–AstraZeneca
 Pfizer–BioNTech
 Sinopharm
 Sinovac
 Bharat Biotech
 Drug development
 Drug repurposing
 Variants of SARS-CoV-2Impact Socio-economic

 Crime
 Ireland
 Death rates by country
 Disability
 Domestic violence
 Economic
 Canada
 India
 Ireland
 New Zealand
 U.K.
 U.S.
 Recession
 Emergency evacuations
 Environment
 Fake treatments
 Financial markets
 Food security
 Hospitals
 Language
 Long-term care
 Migration
 Misinformation
 Governments
 United States
 China
 Military
 Other health issues
 Politics
 Ireland
 Pregnancy
 Prisons
 Religion
 Catholic Church
 Hajj
 LGBT community
 Science and technology
 Social
 New Zealand
 Ireland
 U.K.
 U.S.
 Strikes
 Xenophobia and racism
 Notable deaths
 By industry
 Arts and culture
 Aviation
 Cannabis
 Cinema
 films
 Education
 Ireland
 United Kingdom
 Events affected
 Fashion
 Food
 Canada meat
 U.S. meat
 Journalism
 Music
 Performing arts
 Retail
 Sports
 Ireland
 Philippines
 Television
 U.S.
 programs
 Tourism
 Video gamesclass=noviewer|16x16px COVID-19 portal
BBIBP-CorV, ເຊິ່ງເອີ້ນກັນວ່າ ວັກຊີນ ຊີໂນຟາມ (Sinopharm COVID-19), How the Sinopharm Vaccine Works Jonathan Corum and Carl Zimmer 22 March 2021, www.nytimes.com, accessed 11 April 2021 ແມ່ນ ໜຶ່ງ ໃນສອງ ວັກຊີນ ໄວຣັດຕາຍທີ່ ພັດທະນາໂດຍ Sinopharm . ໃນທ້າຍເດືອນທັນວາປີ 2020, ມັນແມ່ນຢູ່ໃນ ການທົດລອງໄລຍະທີ III ໃນປະ ເທດ Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, ແລະ United Arab Emirates (UAE) ເຊິ່ງມີຜູ້ເຂົ້າຮ່ວມຫຼາຍກວ່າ 60,000 ຄົນ.  BBIBP-CorV ແບ່ງປັນເທັກໂນໂລຊີທີ່ຄ້າຍຄືກັນກັບ CoronaVac ແລະ BBV152, ວັກຊີນໄວຣັດ້ເຊື້ອຕາຍອື່ນໆ ສຳລັບ COVID-19 ທີ່ກຳລັງພັດທະນາໃນການທົດລອງໄລຍະທີ III.  

ວັນທີ 9 ທັນວາ, UAE ໄດ້ປະກາດຜົນຊົ່ວຄາວຈາກການທົດລອງໄລຍະ III ສະແດງໃຫ້ເຫັນວ່າ BBIBP-CorV ມີປະສິດທິຜົນ 86% ຕ້ານການຕິດເຊື້ອ COVID-19.  ໃນທ້າຍເດືອນທັນວາ, Sinopharm ໄດ້ປະກາດວ່າການວິເຄາະພາຍໃນຂອງມັນຊີ້ໃຫ້ເຫັນເຖິງປະສິດທິພາບ 79%.  ໃນຂະນະທີ່ວັກຊີນ mRNA ຄືກັນກັບຢາວັກຊີນ Pfizer – BioNTech COVID-19 ແລະ mRNA-1273 ສະແດງໃຫ້ເຫັນເຖິງປະສິດທິຜົນສູງກວ່າ 90%, ມີຄວາມທ້າທາຍໃນການແຈກຢາຍ ສຳ ລັບບາງປະເທດຍ້ອນວ່າພວກເຂົາຕ້ອງການສິ່ງ ອຳ ນວຍຄວາມສະດວກແລະລົດບັນທຸກທີ່ສາມາດຮັກສາອຸນຫະພມູມໄດ້ດີ. ສ່ວນ BIBP-CorV ສາມາດຂົນສົ່ງແລະເກັບຮັກສາໄວ້ໃນອຸນຫະພູມຕູ້ເຢັນປົກກະຕິ. 

BBIBP-CorV ຖືກ ນຳໃຊ້ເຂົ້າໃນການໂຄສະນາສັກຢາປ້ອງກັນໂດຍບາງປະເທດໃນອາຊີ,    ອາຟຣິກາ,    ອາເມລິກາໃຕ້,    ແລະເອີຣົບ.    Sinopharm ຄາດວ່າຈະສາມາດຜະລິດ BBIBP-CorV ໄດ້ ໜຶ່ງ ພັນລ້ານໂດສ ໃນປີ 2021.  ໃນວັນທີ 26 ມີນາ, Sinopharm ກ່າວວ່າໄດ້ມີການສັກຢາຫຼາຍກວ່າ 80 ລ້ານໂດສໄປແລ້ວ. 

ບໍ່ມີຂໍ້ມູນທາງປະສິດຕິຜົນລະອຽດຂອງຢາວັກຊີນໄດ້ຖືກລົງເຜີຍແຜ່ໃນວາລະສານວິຊາການ.